Anti-angiogenic therapy targeting VEGF or VEGFR-2 has the potential to enhance T cell trafficking to tumours, thereby reducing immunosuppressive cytokines and regulatory T cells, which could help overcome resistance to checkpoint inhibitor therapy (173). This evidence concerns the gene KDR and neoplasm.